Langbahn Team – Weltmeisterschaft

Titan Pharmaceuticals

Titan Pharmaceuticals, Inc.
Company typePublic
NasdaqTTNP
IndustryPharmaceuticals
HeadquartersCalifornia
Key people
RevenueIncrease $1.7 million [2]
Total assetsIncrease $8.4 million [2]
Number of employees
14 (Nov 2018)
Websitetitanpharm.com

Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in San Francisco, CA, developing proprietary therapeutics primarily for treating central nervous system ("CNS") disorders. In September 2018, Titan Pharmaceuticals underwent an IPO wherein it raised $9.5 million in gross proceeds.[3] In the same month, it also posted approximately $1.7 million in revenue, in large part drawn from its licensing for its European intellectual property rights for Probuphine to the Italian pharmaceutical company Molteni - a leading European opioid manufacturer and also a subsidiary of the German Pharmaceutical juggernaut Merck Group.[2][4]

Titan's principal asset is Probuphine,[5][6] a slow-release implant formulation of buprenorphine[7] for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016.[8] It was licensed to Braeburn Pharmaceuticals for marketing and commercialization.[6]

History

The company was founded in 1992 and is headquartered in San Francisco, California.

In 2024, the company entered into a merger agreement and became a wholly-owned subsidiary of BSKE Ltd.[9]

References

  1. ^ "Titan Strengthens Executive Leadership Team With Appointment Of Chief Commercial Officer". Titan Pharmaceuticals, Inc. 2 October 2018.
  2. ^ a b c "Titan Pharmaceuticals Reports Third Quarter 2018 Financial Results". Titan Pharmaceuticals, Inc. 14 November 2018.
  3. ^ "Titan Pharma (TTNP) Prices $9.5M Public Offering".
  4. ^ "Germany's Merck KGaA taking over Molteni Pharma of Italy - Pharmaceuti". www.thepharmaletter.com.
  5. ^ "Technology". Titan Pharmaceuticals, Inc.
  6. ^ a b "Annual Reports". Titan Pharmaceuticals, Inc.
  7. ^ Solof, Barry (2013). The therapist's guide to addiction medicine a handbook for addiction counselors and therapists. New York: Central Recovery Press, LLC. p. 98. ISBN 9781937612443. Retrieved 21 September 2015.
  8. ^ "Press Announcements - FDA approves first buprenorphine implant for treatment of opioid dependence". www.fda.gov. Retrieved 26 May 2016.
  9. ^ "Titan Pharmaceuticals Embarks on Strategic Merger and Restructuring - TipRanks.com". TipRanks Financial. Retrieved 12 December 2024.